Adjunctive Risperidone in Generalized Anxiety Disorder

Brawman‐Mintzer, Olga; Knapp, Rebecca G.; Nietert, Paul J.

doi:10.4088/jcp.v66n1016

Cited by 121 publications

(67 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Á In a placebo-controlled trial with treatmentrefractory GAD patients, adjunctive risperidone was associated with significant improvement (Brawman-Mintzer et al 2005) (B). Á In patients who remained symptomatic remaining symptomatic on fluoxetine, augmentation with olanzapine was superior to adjunctive placebo ) (B).…”

Section: )(D)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Section: )(D)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

show abstract

“…Despite the often benefi cial sedative effects of quetiapine on clinically relevant sleep problems in psychiatric patients, quetipaine is not recommended soley as a sleeping agent. Overall, the most recently available evidence on quetiapine suggests that it can play a signifi cant role in the management of MDD and GAD.For olanzapine or risperidone, it is suggested that the results have been obtained in partialresponders to antidepressants rather than as monotherapy in all patients Brawman& Knapp, 2005).…”

Section: Atypical Antipsychoticsmentioning

confidence: 99%

“…Low doses of risperidone have been shown to improve in anxiety symptoms when added to initial treatment in patients who had not responded to first-line anxiolytic drugs. (Brawman& Knapp ,2005) A study of quetiapine augmentation of paroxetine did not provide evidence as an augmenting agent in GAD. (Simon & Connor,2008).…”

Section: Adequate and Poor Response To Pharmacotherapy: Switching Medmentioning

confidence: 99%

Treatment-Resistant Generalized Anxiety Disorder

Nemeroff¹

2012

Management of Treatment-Resistant Major Psychiatric Disorders

View full text Add to dashboard Cite

“…There has been growing interest in the use of atypical antipsychotics for the treatment of refractory anxiety disorders including GAD with suggestive support for the potential efficacy of adjunctive risperidone (Brawman-Mintzer et al 2005;Simon et al 2006), olanzapine , and aripiprazole (Menza et al 2007), although wellpowered randomized prospective trials are lacking.…”

Section: Background and Significancementioning

confidence: 99%